Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group.
H
H
Chardon
S
S
Farzaneh
R
R
Labia
V
V
Jarlier
M H
MH
Nicolas
G
G
Paul
C
C
Poyart
D
D
Sirot
J
J
Sirot
D000658:Amoxicillin / Q000494:pharmacology; D019980:Amoxicillin-Potassium Clavulanate Combination; D002511:Cephalosporins / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology*; D004927:Escherichia coli Infections / Q000382:microbiology*; D006801:Humans; D007525:Isoelectric Focusing; D013982:Ticarcillin / Q000494:pharmacology; D001618:beta-Lactamases / Q000032:analysis* / Q000096:biosynthesis
D002511:Cephalosporins; D002969:Clavulanic Acids; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; C043215:ticarcillin-clavulanic acid; D001618:beta-Lactamases; D013982:Ticarcillin